Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 9,417 shares, a growth of 116.0% from the August 15th total of 4,359 shares. Based on an average daily trading volume, of 10,401 shares, the short-interest ratio is currently 0.9 days.
Defence Therapeutics Trading Up 5.8%
Shares of DTCFF stock opened at $0.35 on Wednesday. The company’s fifty day moving average price is $0.33 and its two-hundred day moving average price is $0.37. Defence Therapeutics has a 12 month low of $0.25 and a 12 month high of $0.78.
About Defence Therapeutics
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
See Also
- Five stocks we like better than Defence Therapeutics
- 2 “Cheap for a Reason” Airline Stocks That May Be Worth the Risk
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-plc-logo-1200x675.jpg){kind=logo}
